Manufacturing Considerations for Cell and Gene Therapies During COVID-19
FDA published guidance that includes risk-based recommendations for minimizing the potential transmission of COVID-19.
FDA published guidance for industry on Jan. 19, 2021 to provide manufacturers of cell and gene therapies (CGT) with risk-based recommendations for minimizing the potential transmission of COVID-19.The guidance supplements a previous guidance document published in June 2020.
The guidance discusses source materials from donors, including cells and/or tissues. It also discusses cell expansion in culture, viral reduction steps, and formulation. “In light of SARS-CoV-2, FDA recommends that CGT product manufacturers perform a risk assessment that identifies, evaluates, and mitigates factors that may allow for transmission of SARS-CoV-2 by CGT products. A description of the risk assessment and mitigation strategies should be included in the appropriate submission to FDA (e.g., investigational new drug application [IND], biologics license application [BLA], or master file),” FDA states in the guidance document.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
